Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPERIAL-preserved
2017-004072-59Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change from baseline to week 12 in exercise capacity. Started Feb 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2017-004072-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004072-59.